Mental Health Bulletin, July 2008 - NHSGGC



[pic] [pic] [pic]

This bulletin covers aspects of lung cancer and should be of interest to multidisciplinary teams working in this area.

Sections can include:

• Combined Modality Therapies

• Drug Therapy

• Pathology, Staging, Polymorphisms & Biomarkers

• Prognosis, Survival & Risk Factors

• Radiotherapy & Imaging

• Supportive Care & Symptom Management

• Surgery

• Tobacco & Smoking

Many of the following articles are available online via the NHS Scotland Knowledge Network. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at knowledge.scot.nhs.uk/

If the article you require is not available via the NHS Scotland Knowledge Network and you would like to request a print copy, please submit your request online at quest.scot.nhs.uk

This bulletin contains a selection of material gathered from a search of the evidence base, and is not intended to be comprehensive. Professional judgment should be exercised when appraising the material. The Library takes no responsibility for the wording, content and accuracy of the information supplied, which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the content of external internet sites.

Compiled by:

Kirsty Coltart

Subject Librarian

Beatson West of Scotland Cancer Centre

0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk

General

Cardenas-Garcia J, Talwar A, Shah R, et al. (2015). Update in primary pulmonary lymphomas. Current opinion in pulmonary medicine 21,4:333-337.

Prabhakar CN, Fong KM, Peake MD, et al. (2015). The effectiveness of lung cancer MDT and the role of respiratory physicians. Respirology 20,6:884-888.

Combined Modality Therapies

Ahn JS, Ahn YC, Kim JH, et al. (2015). Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. Journal of Clinical Oncology 33,24:2660-2666.

McElnay PJ, Choong A, Jordan E, et al. (2015). Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials. Thorax 70,8:764-768.

Pless M, Stupp R, Ris HB, et al. (2015). Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 386,9998:1049-1056.

Ren Z, Zhou S, Liu Z, et al. (2015). Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis. Journal of Thoracic Disease 7,8:1414-1422.

Singhal N, Mislang A, Karapetis CS, et al. (2015). Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small-cell lung cancer: an open-label phase II multicentre trial (COVeRT study). Anti-Cancer Drugs 26,10:1083-1088.

Wang EH, Corso CD, Rutter CE, et al. (2015). Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 33,25:2727-2734.

Drug & Targeted Therapy

Arcaro, A. (2015). Targeted therapies for small cell lung cancer: Where do we stand? Critical Reviews in Oncology-Hematology 95,2:154-164.

Behera M, Pillai RN, Owonikoko TK, et al. (2015). Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,8:1142-1147.

Evans TL, Cho BC, Udud K, et al. (2015). Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,8:1221-1228.

Farhat FS, Ghosn MG and Kattan JG. (2015). Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer. Cancer Chemotherapy & Pharmacology 76,2:235-242.

Ganti AK, Williams CD, Gajra A, et al. (2015). Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer. Cancer 121,15:2578-2585.

Gettinger SN, Horn L, Gandhi L, et al. (2015). Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 33,18:2004-2012.

HIS (2015). Response to: NICE STA 357. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer

Kanda S, Horinouchi H, Fujiwara Y, et al. (2015). Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer 89,3:287-293.

Kris MG, Camidge DR, Giaccone G, et al. (2015). Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Annals of Oncology 26,7:1421-1427.

Lu S, Yu Y, Chen Z, et al. (2015). Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies. Lung 193,5:805-814.

Matikas A, Mistriotis D, Georgoulias V, et al. (2015). Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs. Clinical Lung Cancer 16,4:252-261.

Petrelli F, Coinu A, Cabiddu M, et al. (2015). Efficacy of fourth-line chemotherapy in advanced non-small-cell lung cancer: a systematic review and pooled analysis of published studies. Anti-Cancer Drugs 26,8:807-812.

Ramalingam S, Goss G, Rosell R, et al. (2015). A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Annals of Oncology 26,8:1741-1748.

Reckamp KL, Koczywas M, Cristea MC, et al. (2015). Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. Cancer 121,18:3298-3306.

Sacher AG, Le LW, Lau A, et al. (2015). Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated? Cancer 121,15:2562-2569.

Shukuya T, Ko R, Mori K, et al. (2015). Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents. Cancer Chemotherapy & Pharmacology 76,4:771-776.

Sjoblom B, Gronberg BH, Benth JS, et al. (2015). Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer 90,1:85-91.

Soria JC, Wu YL, Nakagawa K, et al. (2015). Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncology 16,8:990-998..

Sun JM, Ahn JS, Jung SH, et al. (2015). Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. Journal of Clinical Oncology 33,22:2450-2456.

Syrios J, Nintos G and Georgoulias V. (2015). Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy 15,8:875-884.

Tan CS, Gilligan D and Pacey S. (2015). Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncology 16,9:e447-59.

Vansteenkiste J, Barlesi F, Waller CF, et al. (2015). Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Annals of Oncology 26,8:1734-1740.

Zhao H, Fan Y, Ma S, et al. (2015). Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,4:655-664.

Zhou C, Wu YL, Chen G, et al. (2015). Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Annals of Oncology 26,9:1877-1883.

Pathology, Staging, Polymorphisms & Biomarkers

Callister ME, Baldwin DR, Akram AR, et al. (2015). British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax 70,Suppl 2:1-54.

Cane P, Linklater KM, Nicholson AG, et al. (2015). Morphological and genetic classification of lung cancer: variation in practice and implications for tailored treatment. Histopathology 67,2:216-224.

Carbone DP, Gandara DR, Antonia SJ, et al. (2015). Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,7:974-984.

George J, Lim JS, Jang SJ, et al. (2015). Comprehensive genomic profiles of small cell lung cancer. Nature 524,7563:47-53.

Grohe C, Berardi R and Burst V. (2015). Hyponatraemia-SIADH in lung cancer diagnostic and treatment algorithms. Critical Reviews in Oncology-Hematology 96,1:1-8.

Levy BP, Chioda MD, Herndon D, et al. (2015). Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. Oncologist 20,10:1175-1181.

Prognosis, Survival & Risk Factors

da Silva GT, Bergmann A and Thuler LC. (2015). Prognostic factors in patients with metastatic spinal cord compression secondary to lung cancer: a systematic review of the literature. European Spine Journal 24,10:2107-2113.

Nur U, Quaresma M, De Stavola B, et al. (2015). Inequalities in non-small cell lung cancer treatment and mortality. Journal of Epidemiology & Community Health 69,10:985-992.

Vijayvergia N, Shah PC and Denlinger CS. (2015). Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward. Journal of the National Comprehensive Cancer Network 13,9:1151-1161.

Radiotherapy & Imaging

De Bari B, Filippi AR, Mazzola R, et al. (2015). Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies. Cancer treatment reviews 41,6:511-518.

Hoffmann L, Holt MI, Knap MM, et al. (2015). Anatomical landmarks accurately determine interfractional lymph node shifts during radiotherapy of lung cancer patients. Radiotherapy & Oncology 116,1:64-69.

Kauczor HU, Bonomo L, Gaga M, et al. (2015). ESR/ERS white paper on lung cancer screening. European radiology 25,9:2519-2531.

Koizumi T, Tsushima K, Tanabe T, et al. (2015). Bronchoscopy-Guided Cooled Radiofrequency Ablation as a Novel Intervention Therapy for Peripheral Lung Cancer. Respiration 90,1:47-55.

Konert T, Vogel W, MacManus MP, et al. (2015). PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. Radiotherapy & Oncology 116,1:27-34.

Koshy M, Malik R, Mahmood U, et al. (2015). Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer. Journal of the National Cancer Institute 107,12:

Li H, Becker N, Raman S, et al. (2015). The value of nodal information in predicting lung cancer relapse using 4DPET/4DCT. Medical physics 42,8:4727.

Louie AV, Haasbeek CJ, Mokhles S, et al. (2015). Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model. International journal of radiation oncology, biology, physics 93,1:82-90.

McAleese J, Baluch S and Drinkwater K. (2015). The Quality of Curative-intent Radiotherapy for Non-small Cell Lung Cancer in the UK. Clinical Oncology (Royal College of Radiologists) 27,9:498-504.

Parashar B, Port J, Arora S, et al. (2015). Analysis of stereotactic radiation vs. wedge resection vs. wedge resection plus Cesium-131 brachytherapy in early stage lung cancer. Brachytherapy 14,5:648-654.

Tibdewal A, Munshi A, Pathak R, et al. (2015). Breath-holding times in various phases of respiration and effect of respiratory training in lung cancer patients. Journal of Medical Imaging & Radiation Oncology 59,4:520-526.

Usmanij EA, de Geus-Oei LF, Bussink J, et al. (2015). Update on F-18-fluoro-deoxy-glucose-PET/computed tomography in nonsmall cell lung cancer. Current opinion in pulmonary medicine 21,4:314-321.

Verstegen NE, Lagerwaard FJ, Hashemi SM, et al. (2015). Patterns of Disease Recurrence after SABR for Early Stage Non-Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,8:1195-1200.

Vilmann P, Clementsen PF, Colella S, et al. (2015). Combined endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer. European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). European Respiratory Journal 46,1:40-60.

Weber WA, Gatsonis CA, Mozley PD, et al. (2015). Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials. Journal of Nuclear Medicine 56,8:1137-1143.

Wiener RS, Gould MK, Arenberg DA, et al. (2015). An Official American Thoracic Society/American College of Chest Physicians Policy Statement: Implementation of Low-Dose Computed Tomography Lung Cancer Screening Programs in Clinical Practice. American Journal of Respiratory & Critical Care Medicine 192,7:881-891.

Supportive Care & Symptom Management

Arrieta O, De la Torre-Vallejo M, Lopez-Macias D, et al. (2015). Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. Oncologist 20,8:967-974.

Granger CL, Parry SM and Denehy L. (2015). The self-reported Physical Activity Scale for the Elderly (PASE) is a valid and clinically applicable measure in lung cancer. Supportive Care in Cancer 23,11:3211-3218.

Lehto RH, Wyatt G, Sikorskii A, et al. (2015). Home-based mindfulness therapy for lung cancer symptom management: a randomized feasibility trial. Psycho-oncology 24,9:1208-1212.

Yorke J, Lloyd-Williams M, Smith J, et al. (2015). Management of the respiratory distress symptom cluster in lung cancer: a randomised controlled feasibility trial. Supportive Care in Cancer 23,11:3373-3384.

Surgery

Camposilvan I, Akhtar-Danesh N, Schneider L, et al. (2015). The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries. Journal of Thoracic & Cardiovascular Surgery 150,3:507-513.

de Baere T, Tselikas L, Woodrum D, et al. (2015). Evaluating Cryoablation of Metastatic Lung Tumors in Patients-Safety and Efficacy: The ECLIPSE Trial-Interim Analysis at 1 Year. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,10:1468-1474.

De Waele M and Van Schil P. (2015). Limited resections in high-risk patients. Current opinion in pulmonary medicine 21,4:309-313.

Morgant MC, Pages PB, Orsini B, et al. (2015). Time trends in surgery for lung cancer in France from 2005 to 2012: a nationwide study. European Respiratory Journal 46,4:1131-1139.

Torres MF, Porfirio GJ, Carvalho AP, et al. (2015). Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients. Cochrane Database of Systematic Reviews 9,010355.

Walker BL, Williamson C, Regis SM, et al. (2015). Surgical Outcomes in a Large, Clinical, Low-Dose Computed Tomographic Lung Cancer Screening Program. Annals of Thoracic Surgery 100,4:1218-1223.

Please note that the journal articles you are accessing are subject to the terms and conditions imposed by the publisher, so there will be a limit on the number of articles an individual may download or print from a single issue of a journal. You can consult your local NHSGGC library with any queries.

If you have any questions regarding this or any other library services please contact Library staff – contact details are at the beginning of the bulletin.

Sources used for this bulletin: OVID MEDLINE, SIGN, NICE, Healthcare Improvement Scotland

-----------------------

Lung Cancer

October 2015

-----------------------

7

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download